Mylan gets patent covering transdermal drug Emsam to treat depressive disorder

By E. Janene Geiss

Philadelphia, July 26 - Mylan Laboratories Inc. said Wednesday that U.S. Patent No. 7,070,808 was issued to its subsidiary, Mylan Technologies Inc., on July 4.

The patent contains one or more claims that cover the Emsam transdermal product, which is indicated for the treatment of major depressive disorder, according to a company news release.

Mylan said it granted Somerset Pharmaceuticals Inc. an exclusive license to the patent with respect to the transdermal delivery of selegiline, the active ingredient in Emsam.

Bristol-Myers Squibb distributes the Emsam product, which is manufactured by Mylan for Somerset, officials said.

Emsam is a registered trademark of Somerset Pharmaceuticals.

Mylan is a Pittsburgh, Pa.., pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.